1
|
Liu S, Lyu J, Li Q, Wu X, Yang Y, Huo G, Zhu Q, Guo M, Shen Y, Wang S, Fan C. Generation of a uniform thymic malignant lymphoma model with C57BL/6J p53 gene deficient mice. J Toxicol Pathol 2022; 35:25-36. [PMID: 35221493 PMCID: PMC8828615 DOI: 10.1293/tox.2021-0022] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2021] [Accepted: 08/17/2021] [Indexed: 12/12/2022] Open
Abstract
Lymphoma is the third most common cancer diagnosed in children, and T-cell lymphoma has
the worst prognosis based on clinical observations. To date, a lymphoma model with uniform
penetrance has not yet been developed. In this study, we generated a p53
deficient mouse model by targeting embryonic stem cells derived from a C57BL/6J mouse
strain. Homozygous p53 deficient mice exhibited a higher rate of
spontaneous tumorigenesis, with a high spontaneous occurrence rate (93.3%) of malignant
lymphoma. Because tumor models with high phenotypic consistency are currently needed, we
generated a lymphoma model by a single intraperitoneal injection of 37.5 or 75 mg/kg
N-methyl-N-nitrosourea to p53 deficient mice. Lymphoma and retinal
degeneration occurred in 100% of p53+/− mice administered with
higher concentrations of N-methyl-N-nitrosourea, a much greater response than those of
previously reported models. The main anatomic sites of lymphoma were the thymus, spleen,
bone marrow, and lymph nodes. Both induced and spontaneous lymphomas in the thymus and
spleen stained positive for CD3 antigen, and flow cytometry detected positive CD4 and/or
CD8 cells. Based on our observations and previous data, we hypothesize that mice with a B6
background are prone to lymphomagenesis.
Collapse
Affiliation(s)
- Susu Liu
- Division of Animal Model Research, Institute for Laboratory Animal Resources, National Institutes for Food and Drug Control, No. 31 Huatuo Road, Beijing Daxing district, Beijing 102629, China
| | - Jianjun Lyu
- Department of Pathology, InnoStar Bio-tech Nantong Co., Ltd., Nantong 226133, China
| | - Qianqian Li
- National Centre for Safety Evaluation of Drugs, Institute for Food and Drug Safety Evaluation, National Institutes for Food and Drug Control, A8 Hongda Middle Street, Beijing Economic-Technological Development Area, Beijing 100176, China
| | - Xi Wu
- Division of Animal Model Research, Institute for Laboratory Animal Resources, National Institutes for Food and Drug Control, No. 31 Huatuo Road, Beijing Daxing district, Beijing 102629, China
| | - Yanwei Yang
- National Centre for Safety Evaluation of Drugs, Institute for Food and Drug Safety Evaluation, National Institutes for Food and Drug Control, A8 Hongda Middle Street, Beijing Economic-Technological Development Area, Beijing 100176, China
| | - Guitao Huo
- National Centre for Safety Evaluation of Drugs, Institute for Food and Drug Safety Evaluation, National Institutes for Food and Drug Control, A8 Hongda Middle Street, Beijing Economic-Technological Development Area, Beijing 100176, China
| | - Qingfen Zhu
- Shandong Institute for Food and Drug Control, No. 2749, Xinluo Road, High-tech Zone, Jinan 250101, China
| | - Ming Guo
- Shandong Institute for Food and Drug Control, No. 2749, Xinluo Road, High-tech Zone, Jinan 250101, China
| | - Yuelei Shen
- Beijing Biocytogen Co. LTD, No. 88 Kechuang 6th Avenue Ludong Area Economic-Technological Development Area, Beijing 101111, China
| | - Sanlong Wang
- National Centre for Safety Evaluation of Drugs, Institute for Food and Drug Safety Evaluation, National Institutes for Food and Drug Control, A8 Hongda Middle Street, Beijing Economic-Technological Development Area, Beijing 100176, China
| | - Changfa Fan
- Division of Animal Model Research, Institute for Laboratory Animal Resources, National Institutes for Food and Drug Control, No. 31 Huatuo Road, Beijing Daxing district, Beijing 102629, China
| |
Collapse
|